RenalWEB Dialysis Discussion Boards
  RenalWEB Dialysis Nephrology Kidney Discussion Boards
  General News
  Book: The $800 Million Pill

Post New Topic  Post A Reply
profile | register | preferences | faq | search

UBBFriend: Email This Page to Someone! next newest topic | next oldest topic
Author Topic:   Book: The $800 Million Pill
Gary Peterson
Administrator
posted 01-07-2005 04:38 AM     Click Here to See the Profile for Gary Peterson   Click Here to Email Gary Peterson     Edit/Delete Message   Reply w/Quote
January 7, 2005 - Editor's Note: Two very contrasting pictures are painted by these sets of articles. With Medicare spending likely to be curtailed during this session of Congress, the dialysis community and the pharmaceutical industry will both have to defend their needs.

According to the Medicare Advisory Payment Commission, the use of separately billable drugs administered during dialysis has increased throughout the 1990s and payments for these services represented about 41 percent of Medicare’s total payments to dialysis facilities in 2003. This raises questions as to whether dialysis patients and their advocates should be lobbying for legislation that would redirect some of these current ESRD Medicare pharmaceutical dollars to research, better utilizing these tax dollars instead to seek cures for kidney diseases and to fund kidney-related stem cell research.

(Next week, we'll run the numbers that would be generated by a 10-20% reduction in federal payments for EPO, as well as the likely lobbying actions and campaign contributions that would be involved.)



Book: The $800 Million Pill: The Truth Behind the Cost of New Drugs

The $800 Million Pill suggests ways that the government's role in testing new medicines could be expanded to eliminate the private sector waste driving up the cost of existing drugs. Pharmaceutical firms should be compelled to refocus their human and financial resources on true medical innovation, author Merrill Goozner insists. This book is essential reading for everyone concerned about the politically charged topics of drug pricing, Medicare coverage, national health care, and the role of pharmaceutical companies in developing countries. (The University of California Press)

Related reviews, commentaries and articles:




Last month:

Previous battles between dialysis providers and Amgen are detailed in these news summaries:


[This message has been edited by Gary Peterson (edited 01-12-2005).]

IP: 24.60.234.30

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | RenalWEB Home Page


Ultimate Bulletin Board 5.47e

Copyright 2004. No material on these discussion boards may be reproduced without permission from RenalWEB.